<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178863</url>
  </required_header>
  <id_info>
    <org_study_id>2019004</org_study_id>
    <nct_id>NCT04178863</nct_id>
  </id_info>
  <brief_title>CATS Tonometer IOP Reduction Latanoprost Verses Timolol</brief_title>
  <official_title>Efficacy of Topical Latanoprost 0.005% Verses Timolol 0.5% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intuor Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intuor Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Topical Prostaglandin Analog vs Betablocker - Corneal Biomechanical Evaluation using CATS
      Tonometer Prism
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is a prospective, controlled, study and will be performed at one clinical
      investigative site in Tucson Arizona1. The purpose of this study is to determine if the
      device, CATS tonometer prism, measures intraocular pressure significantly differently than
      the current standard of care tonometer prism (Goldmann) before and after institution of
      topical prostaglandin analogs (PGA) for glaucoma treatment. Fifty percent of patients will be
      randomly placed on topical beta blockers as a control. The difference PGAs and beta blockers
      would be a measurement of the amount of corneal biomechanical changes made due to the PGA
      controlled for the effect of IOP lowering by the beta -blocker group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IOP reduction</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Glaucoma; Drugs</condition>
  <arm_group>
    <arm_group_label>lataprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>latanoprost use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>timolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>timolol group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CATS Tonometer</intervention_name>
    <description>latanoprost vs. timolol</description>
    <arm_group_label>lataprost</arm_group_label>
    <arm_group_label>timolol</arm_group_label>
    <other_name>latanoprost v. timolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost</intervention_name>
    <description>latanoprost IOP reduction</description>
    <arm_group_label>timolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â€¢ Male and female patients, at least 18 years of age

               -  Subject has a clear understanding and agrees to all the conditions of the
                  informed consent form

        Exclusion Criteria:

          -  Subjects shall be selected in accordance with the following exclusion criteria

               -  Subject has undergone ocular surgery within the last 3 months

               -  Uncontrolled systemic disease that in the opinion of the Investigator would put
                  the subject's heath at risk

               -  Pregnant or nursing women

               -  Those who have had corneal surgery including corneal laser surgery

               -  Microphthalmos

               -  Buphthalmos

               -  Severe Dry eyes

               -  Lid squeezers - blepharospasm

               -  Nystagmus

               -  corneal or conjunctival infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>101 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Eye Consultants</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean McCafferty, MD</last_name>
      <phone>520-400-4255</phone>
      <email>sjmccafferty66@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 23, 2019</study_first_submitted>
  <study_first_submitted_qc>November 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>November 23, 2019</last_update_submitted>
  <last_update_submitted_qc>November 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

